-

Forbes Names Zoetis One of America’s Best Midsize Employers

PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE: ZTS), the global leader in animal health, today announced that it has been named one of America’s Best Midsize Employers by Forbes Magazine for the fifth time.

“At Zoetis, our colleagues drive our success and shape our reputation as a top employer,” said Roxanne Lagano, Executive Vice President, Chief Human Resources Officer and Global Operations. “We continue to build a diverse and inclusive culture - based on our Core Beliefs – where everyone can thrive, both personally and professionally. We are proud to consistently be recognized by Forbes as one of America’s Best Midsize Employers, and we thank our colleagues for recommending Zoetis as a great place to work.”

Forbes determined its America’s Best Employers list based on an independent survey among a sample of 50,000 American employees working for companies with at least 1,000 people in their U.S. operations. The willingness to recommend one's own employer was used as the most important factor in the assessment. The employees were consulted anonymously through online access panels which allowed them to express their opinions. Visit Forbes.com for more details about the list of America’s Best Midsize Employers.

Award-Winning Culture

Zoetis has consistently been recognized as a great place to work. The company has been named among the Top Companies for Working Mothers for the past seven years, as well as a Top Company for Executive Women for three years in a row. Most recently, Zoetis received a score of 100 percent on the Human Rights Campaign Foundation’s 2021 Corporate Equality Index (CEI), the nation’s foremost benchmarking survey and report measuring corporate policies and practices related to LGBTQ workplace equality.

Learn More

For more information about Zoetis, including career opportunities, our commitment to Diversity, Equity and Inclusion, and our award-winning culture, visit https://careers.zoetis.com/.

About Zoetis

Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses.

Building on more than 65 years of experience in animal health, Zoetis discovers, develops, manufactures and commercializes medicines, vaccines and diagnostic products, which are complemented by biodevices, genetic tests and precision livestock farming. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. In 2019, the company generated annual revenue of $6.3 billion with approximately 10,600 employees. For more information, visit www.zoetis.com.

ZTS-COR

Contacts

Media Contacts:
Bill Price
1-973-443-2742 (o)
william.price@zoetis.com

Kristen Seely
1-973-443-2777 (o)
kristen.seely@zoetis.com

Zoetis Inc.

NYSE:ZTS

Release Summary
Zoetis has been named one of America’s Best Midsize Employers by Forbes Magazine for the fifth time.
Release Versions
$Cashtags

Contacts

Media Contacts:
Bill Price
1-973-443-2742 (o)
william.price@zoetis.com

Kristen Seely
1-973-443-2777 (o)
kristen.seely@zoetis.com

Social Media Profiles
More News From Zoetis Inc.

Zoetis Announces Second Quarter 2026 Results

PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS), the world's leading animal health company, today reported its financial results for the second quarter of 2026. The company reported revenue of $2.5 billion for the second quarter of 2026, flat compared with the second quarter of 2025, decreasing 1% on an organic operational1 basis. Net income for the second quarter of 2026 was $691 million, or $1.65 per diluted share, decreasing 5% and growing 1%, respectively, on a reported basis. Adj...

Zoetis Appoints Jay Saccaro as Chief Financial Officer and Chief Operating Officer

PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE: ZTS) today announced the appointment of James (Jay) Saccaro as Executive Vice President, Chief Financial Officer and Chief Operating Officer, effective August 17, 2026. In this newly created role, Mr. Saccaro will lead Zoetis’ global finance function, shaping capital allocation, financial strategy, reporting and controls, and investor engagement and oversee Global Manufacturing and Supply to drive operational execution and performance. With...

Zoetis Launches Portela® (relfovetmab) in Canada and the European Union

PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE: ZTS) today announced the commercial launch of Portela® (relfovetmab) in Canada and the European Union (EU) member states. Portela is the first long-acting anti-nerve growth factor (NGF) monoclonal antibody (mAb) therapy for cats, designed to alleviate pain associated with osteoarthritis (OA) for up to three months with a single subcutaneous injection. Backed by nearly a decade of science and research, Portela demonstrated effectiveness in al...
Back to Newsroom